GlassScriptPhysician profile
Arvind Bhimaraj
NPI 1275864878
$216,052.36
in general payments reported to CMS, 2019-2025
35 companies · $41K in 2025
The $41K reported for 2025 was more than what 91% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $13K · 2021: $58K · 2022: $12K · 2023: $18K · 2024: $36K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $44K · Travel and Lodging: $17K · Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Honoraria: $7,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,937.50 |
| Travel and Lodging | $16,759.85 |
| Food and Beverage | $13,134.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,700.00 |
| Honoraria | $7,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $100,146.34 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Astrazeneca Pharmaceuticals LP | $52,214.20 | 2020-2025 | Farxiga, Wainua, Brilinta |
| Abiomed | $39,031.15 | 2019-2025 | Impella |
| Pfizer INC. | $5,982.28 | 2019-2025 | |
| Getinge USA Sales, LLC | $5,919.17 | 2021-2025 | Cardiohelp, Cardiosave Hybrid, Type B Plug, Vasoview Hemopro 2 |
| Sanofi-Aventis U.S. LLC | $4,572.00 | 2021 | |
| Cvrx, INC. | $2,284.71 | 2021-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $1,405.43 | 2021-2025 | Optimizer, Optimizer |
| Alnylam Pharmaceuticals INC. | $905.18 | 2019-2025 | Onpattro, Amvuttra |
| Paragonix Technologies, INC. | $420.87 | 2024 | Liverguard, Sherpapak, Pancreaspak |
| Atricure, INC. | $323.53 | 2022-2023 | |
| Datascope Corp. | $322.99 | 2023-2025 | Cardiosave Rescue, Cardiosave Hybrid, Type B Plug |
| Medtronic Vascular, INC. | $295.81 | 2019 | |
| Amgen INC. | $290.59 | 2019-2024 | Repatha |
| Bridgebio Pharma, INC. | $230.50 | 2025 | Attruby |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $217.46 | 2019-2025 | Uptravi, Opsumit |
| Medtronic, INC. | $174.22 | 2023-2024 | Corevalve Evolut R |
| Boston Scientific Corporation | $160.01 | 2019 | |
| Inari Medical, INC. | $140.38 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $137.50 | 2019-2024 | |
| Zoll Respicardia, INC. | $123.42 | 2019 | |
| Silk Road Medical, INC. | $97.31 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.49 | 2022-2024 | Jardiance |
| Pulmonx Corporation | $91.69 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| E.R. Squibb & Sons, L.L.C. | $85.59 | 2024-2025 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $79.06 | 2025 | Livtencity |
| Kamada LTD. | $75.67 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $45.24 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $44.27 | 2024 | |
| Janssen Pharmaceuticals, INC | $38.63 | 2019-2022 | |
| Daiichi Sankyo INC. | $24.75 | 2024 | Injectafer |
| Haemonetics Corporation | $23.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.37 | 2019 | |
| Novo Nordisk INC | $18.45 | 2025 | Wegovy |
| Tactile Systems Technology INC | $13.50 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Bhimaraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.